


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


- 1) **(Previously Presented)** A compound of formula (I)



I

or a pharmaceutically acceptable salt, wherein

A is phenyl, naphthyl, pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, benzoxazole, indazole, quinoline, quinazoline, imidazopyrimidine, naphthyridine, or a group of the formula



optionally substituted with 1-4 substituents which are independently  $R^1$ ,  $OR^1$ ,  $S(O)_pR^1$ ,  $C(O)R^1$ ,  $C(O)OR^1$ ,  $C(O)NR^1R^2$ , halogen, hydroxy, oxide, amino, cyano, or nitro;

B is phenyl, naphthyl, or pyridyl, optionally substituted with 1-4 substituents which are independently  $C_1$ - $C_5$  linear or branched alkyl,  $C_1$ - $C_5$  linear or branched haloalkyl,  $C_1$ - $C_3$  alkoxy, hydroxy, oxide, amino,  $C_1$ - $C_3$  alkylamino,  $C_1$ - $C_6$  dialkylamino, halogen, cyano, or nitro;

L is

(a)  $-(CH_2)_m-O-(CH_2)_l-$ ,

(b)  $-(CH_2)_m-(CH_2)_l-$ ,


- (c)  $-(CH_2)_m-C(O)-(CH_2)_l-$ ,
- (d)  $-(CH_2)_m-NR^3-(CH_2)_l-$ ,
- (e)  $-(CH_2)_m-NR^3C(O)-(CH_2)_l-$ ,
- (f)  $-(CH_2)_m-S-(CH_2)_l-$ ,
- (g)  $-(CH_2)_m-C(O)NR^3-(CH_2)_l-$ , or
- (h) a single bond;

m and l are integers independently selected from 0-4;

M is a pyridine ring, optionally substituted with 1-3 substituents which are independently  $C_1$ - $C_5$  linear or branched alkyl,  $C_1$ - $C_5$  linear or branched haloalkyl,  $C_1$ - $C_3$  alkoxy, hydroxy, oxide, amino,  $C_1$ - $C_3$  alkylamino,  $C_1$ - $C_6$  dialkylamino, halogen, or nitro;

Q is:

- (1)  $C(S)NR^4R^5$ ;
- (2)  $C(O)NR^7-NR^4R^5$ ;
- (3) tetrazolyl;
- (4) imidazolyl;
- (5) imidazoline-2-yl;
- (6) 1,3,4-oxadiazoline-2-yl;
- (7) 1,3-thiazoline-2-yl;
- (8) 5-thioxo-4,5-dihydro-1,3,4-thiazoline-2-yl;
- (9) 5-oxo-4,5-dihydro-1,3,4-oxadiazoline-2-yl; or
- (10) a group of the formula



wherein each of  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  is independently

- (a) hydrogen,
- (b)  $C_1$ - $C_5$  linear, branched, or cyclic alkyl,

- (c) phenyl,
- (d) C<sub>1</sub>-C<sub>3</sub> phenyl-alkyl,
- (e) up to per-halo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, or
- (f) -(CH<sub>2</sub>)<sub>q</sub>-X, where X is a tetrahydropyran, tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidinone, tetrahydropyrimidine, pentamethylene sulfide, tetramethylene sulfide, dihydropyran, dihydrofuran, dihydrothiophene, pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine or benzoxazole, indazole, quinoline, quinoxaline, imidazopyrimidine or naphthyridine;

R<sup>4</sup> and R<sup>5</sup> may additionally be taken together to form a 5 or 6 membered aliphatic ring, which may be interrupted by an atom selected from N, O or S, optionally substituted with 1-3 substituents which are independently C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, up to perhalo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy, oxo, carboxy, amino, C<sub>1</sub>-C<sub>3</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> dialkylamino, halogen, cyano, or nitro;

R<sup>6</sup> is independently

- (a) hydrogen,
- (b) C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl,
- (c) cyano,
- (d) nitro,
- (e) up to per-halo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl. or
- (f) -C(O)R<sup>7</sup>, where R<sup>7</sup> is C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl;

R<sup>7</sup> is hydrogen or linear, branched, or cyclic C<sub>1</sub>-C<sub>5</sub> alkyl;


q is an integer 0, 1, 2, 3, or 4 and

p is an integer 0, 1, or 2.

2) **(Original)** A compound of claim 1 wherein B is phenyl or pyridinyl, optionally substituted with 1-4 halogen.

3) **(Previously Presented)** A compound of claim 1 wherein L is  $-\text{O}-$  and B is phenyl, optionally substituted with 1-4 halogen.

4) **(Previously Presented)** A compound of formula (I)




or a pharmaceutically acceptable salt, wherein A is phenyl, naphthyl, indazolyl, quinolinyl, pyridyl, benzo[1,3]dioxolan-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl or 4H-benzo[1,3]dioxin-6-yl, optionally substituted with 1-4 substituents which are independently  $\text{R}^1$  and halogen,

L is  $-\text{O}-$  and B is phenyl, optionally substituted with 1-4 halogen;

M is a pyridine ring, optionally substituted with 1-3 substituents which are independently  $\text{C}_1\text{-C}_5$  linear or branched alkyl,  $\text{C}_1\text{-C}_5$  linear or branched haloalkyl,  $\text{C}_1\text{-C}_3$  alkoxy, hydroxy, oxide, amino,  $\text{C}_1\text{-C}_3$  alkylamino,  $\text{C}_1\text{-C}_6$  dialkylamino, halogen, or nitro;

Q is:

- (1)  $\text{C}(\text{S})\text{NR}^4\text{R}^5$ ;
- (2)  $\text{C}(\text{O})\text{NR}^7\text{-NR}^4\text{R}^5$ ;
- (3) tetrazolyl;
- (4) imidazolyl;
- (5) imidazoline-2-yl;
- (6) 1,3,4-oxadiazoline-2-yl;
- (7) 1,3-thiazoline-2-yl;
- (8) 5-thioxo-4,5-dihydro-1,3,4-thiazoline-2-yl;
- (9) 5-oxo-4,5-dihydro-1,3,4-oxadiazoline-2-yl; or
- (10) a group of the formula



wherein each of  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  is independently

- (a) hydrogen,
- (b)  $C_1$ - $C_5$  linear, branched, or cyclic alkyl,
- (c) phenyl,
- (d)  $C_1$ - $C_3$  phenyl-alkyl,
- (e) up to per-halo substituted  $C_1$ - $C_5$  linear or branched alkyl, or
- (f)  $-(CH_2)_q-X$ , where X is tetrahydropyran, tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidinone, tetrahydropyrimidine, pentamethylene sulfide, tetramethylene sulfide, dihydropyran, dihydrofuran, dihydrothiophene, pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine or benzoxazole, indazole, quinoline, quinazoline, imidazopyrimidine or naphthyridine;

$R^4$  and  $R^5$  may additionally be taken together to form a 5 or 6 membered aliphatic ring, which may be interrupted by an atom selected from N, O or S, optionally substituted with 1-3 substituents which are independently  $C_1$ - $C_5$  linear or branched alkyl, up to perhalo substituted  $C_1$ - $C_5$  linear or branched alkyl,  $C_1$ - $C_3$  alkoxy, hydroxy, oxo, carboxy, amino,  $C_1$ - $C_3$  alkylamino,  $C_1$ - $C_6$  dialkylamino, halogen, cyano, or nitro;

$R^6$  is independently

- (a) hydrogen,
- (b)  $C_1$ - $C_5$  linear, branched, or cyclic alkyl,
- (c) cyano,
- (d) nitro,
- (e) up to per-halo substituted  $C_1$ - $C_5$  linear or branched alkyl. or
- (f)  $-C(O)R^7$ , where  $R^7$  is  $C_1$ - $C_5$  linear, branched, or cyclic alkyl;

R<sup>7</sup> is hydrogen or linear, branched, or cyclic C<sub>1</sub>-C<sub>5</sub> alkyl;

q is an integer 0, 1, 2, 3, or 4 and

p is an integer 0, 1, or 2.

5) **(Original)** A compound of claim 1

wherein A and B follow one of the following combinations:

- A= phenyl and B= phenyl,
- A= indazolyl and B= phenyl,
- A= quinoliny and B= phenyl,
- A= 4H-benzo[1,3]dioxin-6-yl and B= phenyl;
- A= phenyl and B= pyridyl,
- A= indazolyl and B= pyridyl,
- A= quinoliny and B= pyridyl, or
- A= 4H-benzo[1,3]dioxin-6-yl and B= pyridyl.

6) **(Original)** A compound which is

- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-([2-(hydrazinocarbonyl)pyridin-4-yl]oxy)phenyl)urea
- N-(4-([2-(hydrazinocarbonyl)pyridin-4-yl]oxy)phenyl)-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-({2-[(2,2-dimethylhydrazino)carbonyl]pyridin-4-yl}oxy)phenyl]urea
- 4-{3-([4-chloro-3-(trifluoromethyl)phenyl]amino)carbonyl}amino]phenoxy}-N-piperidin-1-ylpyridine-2-carboxamide
- N-piperidin-1-yl-4-[3-({[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl}amino)phenoxy]pyridine-2-carboxamide
- 4-{3-([4-chloro-3-(trifluoromethyl)phenyl]amino)carbonyl}amino]phenoxy}-N-morpholin-4-ylpyridine-2-carboxamide
- N-morpholin-4-yl-4-[3-({[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl}amino)phenoxy]pyridine-2-carboxamide
- 4-[3-({[(1-methyl-1H-indazol-5-yl)amino]carbonyl}amino)phenoxy]-N-morpholin-4-

ylpyridine-2-carboxamide

- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(1H-tetrazol-5-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(4,5-dihydro-1H-imidazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(4-methyl-1,3-thiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-quinolin-6-yl-N'-(4-{[2-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-(4-{[2-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea
- 4-{4-([4-chloro-3-(trifluoromethyl)phenyl]amino)carbonyl)amino]phenoxy}-N-methylpyridine-2-carboximidamide
- 4-{4-([4-chloro-3-(trifluoromethyl)phenyl]amino)carbonyl)amino]phenoxy}pyridine-2-carboximidamide
- N-methyl-4-[4-([2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl]amino)carbonyl)amino]phenoxy]pyridine-2-carboximidamide
- N-methyl-4-(4-([(quinolin-6-ylamino)carbonyl]amino)phenoxy)pyridine-2-carboximidamide
- 4-{4-([4-chloro-3-(trifluoromethyl)phenyl]amino)carbonyl)amino]phenoxy}pyridine-2-carbothioamide
- 4-(4-([(quinolin-6-ylamino)carbonyl]amino)phenoxy)pyridine-2-carbothioamide or
- 4-[4-([(1-methyl-1H-indazol-5-yl)amino)carbonyl]amino)phenoxy]pyridine-2-carbothioamide

7) **(Original)** A pharmaceutical composition which comprises an effective amount of at least one compound of claim 1 and a physiologically acceptable carrier.

8) **(Withdrawn)** A method for treating or preventing a hyper-proliferative disorder in a human or other mammal comprising administering to a human or other mammal in need thereof a compound of claim 1.

9) **(Withdrawn)** A method for treating or preventing a hyper-proliferative disorder in a human or other mammal comprising administering to a human or other mammal in need thereof a compound of claim 1 and an additional anti-proliferative agent.

10) **(Withdrawn)** A method for treating or preventing cancer in a human or other mammal comprising administering to a human or other mammal in need thereof a compound of claim 1 and a cytotoxic agent or cytostatic chemotherapeutic agent.

11) **(Withdrawn)** A method for treating or preventing a disease in a human or other mammal regulated by tyrosine kinase, associated with an aberration in the tyrosine kinase signal transduction pathway, comprising administering to a human or other mammal in need thereof a compound of claim 1.

12) **(Withdrawn)** A method for treating or preventing a disease in a human or other mammal mediated by the VEGF-induced signal transduction pathway, comprising administering to a human or other mammal in need thereof a compound of claim 1.

13) **(Withdrawn)** A method for treating or preventing a disease in a human or other mammal characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to a human or other mammal in need thereof a compound of claim 1.

14) **(Withdrawn)** A method for treating or preventing a disease in a human or other mammal characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to a human or other mammal in need thereof a compound of claim 1 simultaneously with another angiogenesis inhibiting agent in the same formulation or in separate formulations.



15) **(Withdrawn)** A method for treating or preventing one or more of the following conditions in humans and/or other mammals: tumor growth, retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, a bolus disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, or dermatitis herpetiformis, comprising administering to a human or other mammal in need thereof a compound of claim 1.

16) **(Withdrawn)** A method for treating or preventing one or more of the following conditions in humans and/or other mammals: tumor growth, retinopathy, diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, bullous disorder associated with subepidermal blister formation, bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis, in combination with an infectious disease selected from the group consisting of: tuberculosis, Helicobacter pylori infection during peptic ulcer disease, Chaga's disease resulting from Trypanosoma cruzi infection, effects of Shiga-like toxin resulting from E. coli infection, effects of enterotoxin A resulting from Staphylococcus infection, meningococcal infection, and infections from Borrelia burgdorferi, Treponema pallidum, cytomegalovirus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (HIV),

said method comprising administering to a human or other mammal in need thereof a compound of claim 1.

17) **(Withdrawn)** A method for treating or preventing diseases mediated by the VEGF-induced signal transduction pathway comprising administering a compound selected from the group consisting of:

- 4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carbothioic acid amide;
- 4-{3-[3-(2,2,4,4-Tetrafluoro-4H-benzo[1,3]dioxin-6-yl)-ureido]-phenoxy}-pyridine-2-carboxylic acid (1-piperidyl)-amide;

- 4-{3-[3-(2,2,4,4-Tetrafluoro-4H-benzo[1,3]dioxin-6-yl)-ureido]-phenoxy}-pyridine-2-carboxylic acid (4-morpholino)-amide;
- 4-{3-[3-(1-Methyl-1H-indazol-5-yl)-ureido]-phenoxy}-pyridine-2-carboxylic acid (4-morpholino)-amide;
- 4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxamidine;
- 1-(4-Chloro-3-trifluoromethyl-phenyl)-3-{4-[2-(1H-tetrazol-5-yl)-pyridinyl-4-oxy]-phenyl}-urea;
- 1-(4-Chloro-3-trifluoromethyl-phenyl)-3-{4-[2-(4,5-dihydro-1H-imidazol-2-yl)-pyridinyl-4-oxy]-phenyl}-urea;
- 4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-N-methyl-pyridine-2-carboxamidine;


or a salt form, prodrug or metabolite thereof.

18) **(Withdrawn)** A method for treating or preventing cancer comprising administering a compound selected from the group consisting of:

- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-[[2-(hydrazinocarbonyl)pyridin-4-yl]oxy]phenyl)urea
- N-(4-[[2-(hydrazinocarbonyl)pyridin-4-yl]oxy]phenyl)-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-({2-[(2,2-dimethylhydrazino)carbonyl]pyridin-4-yl}oxy)phenyl]urea
- 4-{3-[[{4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino]phenoxy}-N-piperidin-1-ylpyridine-2-carboxamide
- N-piperidin-1-yl-4-[3-({[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl}amino)phenoxy]pyridine-2-carboxamide
- 4-{3-[[{4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino]phenoxy}-N-morpholin-4-ylpyridine-2-carboxamide
- N-morpholin-4-yl-4-[3-({[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl}amino)phenoxy]pyridine-2-carboxamide
- 4-[3-({[(1-methyl-1H-indazol-5-yl)amino]carbonyl}amino)phenoxy]-N-morpholin-4-ylpyridine-2-carboxamide

- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-[[2-(1H-tetrazol-5-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-[[2-(4,5-dihydro-1H-imidazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-[[2-(1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-[[2-(4-methyl-1,3-thiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-quinolin-6-yl-N'-(4-[[2-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-[[2-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-(4-[[2-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea
- 4-{4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino}phenoxy}-N-methylpyridine-2-carboximidamide
- 4-{4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino}phenoxy}pyridine-2-carboximidamide
- N-methyl-4-[4-(((2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino)carbonyl)amino]phenoxy}pyridine-2-carboximidamide
- N-methyl-4-(4-[[[quinolin-6-ylamino]carbonyl]amino]phenoxy)pyridine-2-carboximidamide
- 4-{4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino}phenoxy}pyridine-2-carbothioamide
- 4-(4-[[[quinolin-6-ylamino]carbonyl]amino]phenoxy)pyridine-2-carbothioamide
- 4-[4-(((1-methyl-1H-indazol-5-yl)amino)carbonyl)amino]phenoxy}pyridine-2-carbothioamide, or a salt form, prodrug or metabolite thereof.


19) **(Previously Presented)** A compound of formula (I)



I

or a pharmaceutically acceptable salt thereof, wherein

A is



wherein A is optionally substituted with 1-4 substituents which are independently  $\text{R}^1$ ,  $\text{OR}^1$ ,  $\text{S}(\text{O})_p\text{R}^1$ ,  $\text{C}(\text{O})\text{R}^1$ ,  $\text{C}(\text{O})\text{OR}^1$ ,  $\text{C}(\text{O})\text{NR}^1\text{R}^2$ , halogen, hydroxy, oxide, amino, cyano, or nitro;

B is phenyl, or pyridyl, optionally substituted with 1-4 substituents which are independently  $\text{C}_1$ - $\text{C}_5$  linear or branched alkyl,  $\text{C}_1$ - $\text{C}_5$  linear or branched haloalkyl,  $\text{C}_1$ - $\text{C}_3$  alkoxy, hydroxy, oxide, amino,  $\text{C}_1$ - $\text{C}_3$  alkylamino,  $\text{C}_1$ - $\text{C}_6$  dialkylamino, halogen, cyano, or nitro;

L is


- (a)  $-(\text{CH}_2)_m-\text{O}-(\text{CH}_2)_l-$ ,
- (b)  $-(\text{CH}_2)_m-(\text{CH}_2)_l-$ ,
- (c)  $-(\text{CH}_2)_m-\text{C}(\text{O})-(\text{CH}_2)_l-$ ,
- (d)  $-(\text{CH}_2)_m-\text{NR}^3-(\text{CH}_2)_l-$ ,
- (e)  $-(\text{CH}_2)_m-\text{NR}^3\text{C}(\text{O})-(\text{CH}_2)_l-$ ,
- (f)  $-(\text{CH}_2)_m-\text{S}-(\text{CH}_2)_l-$ ,
- (g)  $-(\text{CH}_2)_m-\text{C}(\text{O})\text{NR}^3-(\text{CH}_2)_l-$ , or
- (h) a single bond;

m and l are integers independently selected from 0-4;

M is a pyridine ring, optionally substituted with 1-3 substituents which are independently C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy, oxide, amino, C<sub>1</sub>-C<sub>3</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> dialkylamino, halogen, or nitro;

Q is:

- (1) C(S)NR<sup>4</sup>R<sup>5</sup>;
- (2) C(O)NR<sup>7</sup>-NR<sup>4</sup>R<sup>5</sup>;
- (3) tetrazolyl;
- (4) imidazolyl;
- (5) imidazoline-2-yl;
- (6) 1,3,4-oxadiazoline-2-yl;
- (7) 1,3-thiazoline-2-yl;
- (8) 5-thioxo-4,5-dihydro-1,3,4-thiazoline-2-yl;
- (9) 5-oxo-4,5-dihydro-1,3,4-oxadiazoline-2-yl; or
- (10) a group of the formula



wherein each of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is independently

- (a) hydrogen,
- (b) C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl,
- (c) phenyl,
- (d) C<sub>1</sub>-C<sub>3</sub> phenyl-alkyl,
- (e) up to per-halo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, or
- (f) -(CH<sub>2</sub>)<sub>q</sub>-X, where X is a tetrahydropyran, tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidinone, tetrahydropyrimidone, pentamethylene sulfide, tetramethylene sulfide, dihydropyran, dihydrofuran, dihydrothiophene, pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, pyridine,

pyrimidine, pyridazine, pyrazine, triazine or benzoxazole, indazole, quinoline, quinazoline, imidazopyrimidine or naphthyridine;

$R^4$  and  $R^5$  may additionally be taken together to form a 5 or 6 membered aliphatic ring, which may be interrupted by an atom selected from N, O or S, optionally substituted with 1-3 substituents which are independently  $C_1$ - $C_5$  linear or branched alkyl, up to perhalo substituted  $C_1$ - $C_5$  linear or branched alkyl,  $C_1$ - $C_3$  alkoxy, hydroxy, oxo, carboxy, amino,  $C_1$ - $C_3$  alkylamino,  $C_1$ - $C_6$  dialkylamino, halogen, cyano, or nitro;

$R^6$  is independently

- (a) hydrogen,
- (b)  $C_1$ - $C_5$  linear, branched, or cyclic alkyl,
- (c) cyano,
- (d) nitro,
- (e) up to per-halo substituted  $C_1$ - $C_5$  linear or branched alkyl. or
- (f)  $-C(O)R^7$ , where  $R^7$  is  $C_1$ - $C_5$  linear, branched, or cyclic alkyl;

$R^7$  is hydrogen or linear, branched, or cyclic  $C_1$ - $C_5$  alkyl;

q is an integer 0, 1, 2, 3, or 4 and

p is an integer 0, 1, or 2.

20) **(Original)** A compound of claim 19 wherein B is phenyl or pyridinyl, optionally substituted with 1-4 halogen.

21) **(Original)** A compound of claim 19 wherein L is  $-O-$  and B is phenyl or pyridinyl, optionally substituted with 1-4 halogen.

22) **(Original)** A compound as in claim 19 wherein B is phenyl or pyridyl, L is  $-O-$ ,


M a pyridine ring substituted only by Q, and Q is

$C(S)NR^4R^5$ ;

$C(O)NR^7-NR^4R^5$ ;

or

a group of the formula




with each of R<sup>4</sup> and R<sup>5</sup>, independently:

- (a) hydrogen,
- (b) C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl,
- (c) phenyl,
- (d) C<sub>1</sub>-C<sub>3</sub> phenyl-alkyl,
- (e) up to per-halo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, or
- (f) -(CH<sub>2</sub>)<sub>q</sub>-X, where the substituent X is pyridinyl and the variable q is preferably an integer 0 or 1, and

R<sup>6</sup> is:

- (a) hydrogen,
- (b) C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl, or
- (c) cyano.


23) **(Previously Presented)** A compound of formula (I)




I

or a pharmaceutically acceptable salt thereof, wherein

A is



or



wherein A is optionally substituted with 1-4 substituents which are independently  $R^1$ ,  $OR^1$ , or halogen


B is phenyl or pyridinyl, optionally substituted with 1-4 substituents which are independently  $C_1$ - $C_5$  linear or branched alkyl,  $C_1$ - $C_5$  linear or branched haloalkyl,  $C_1$ - $C_3$  alkoxy, hydroxy, oxide, amino,  $C_1$ - $C_3$  alkylamino,  $C_1$ - $C_6$  dialkylamino, halogen, cyano, or nitro,

L is -O-,

M is a pyridine ring,

Q is:

- (1)  $C(S)NR^4R^5$ ;
- (2)  $C(O)NR^7-NR^4R^5$ ;
- (3) tetrazolyl;
- (4) imidazolyl;
- (5) imidazoline-2-yl;
- (6) 1,3,4-oxadiazoline-2-yl;
- (7) 1,3-thiazoline-2-yl;
- (8) 5-thioxo-4,5-dihydro-1,3,4-thiazoline-2-yl;
- (9) 5-oxo-4,5-dihydro-1,3,4-oxadiazoline-2-yl; or
- (10) a group of the formula



wherein each of  $R^1$ ,  $R^4$  and  $R^5$  is independently

- (a) hydrogen,
- (b)  $C_1$ - $C_5$  linear, branched, or cyclic alkyl,
- (c) phenyl,
- (d)  $C_1$ - $C_3$  phenyl-alkyl,



(e) up to per-halo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, or  
(f) -(CH<sub>2</sub>)<sub>q</sub>-X, where X is a tetrahydropyrane, tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidinone, tetrahydropyrimidine, pentamethylene sulfide, tetramethylene sulfide, dihydropyrane, dihydrofuran, dihydrothiophene, pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine or benzoxazole, indazole, quinoline, quinazoline, imidazopyrimidine or naphthyridine;

R<sup>4</sup> and R<sup>5</sup> may additionally be taken together to form a 5 or 6 membered aliphatic ring, which may be interrupted by an atom selected from N, O or S, optionally substituted with 1-3 substituents which are independently C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, up to perhalo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy, oxo, carboxy, amino, C<sub>1</sub>-C<sub>3</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> dialkylamino, halogen, cyano, or nitro;

R<sup>6</sup> is independently

- (a) hydrogen,
- (b) C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl,
- (c) cyano,
- (d) nitro,
- (e) up to per-halo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl. or
- (f) -C(O)R<sup>7</sup>, where R<sup>7</sup> is C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl;

R<sup>7</sup> is hydrogen or linear, branched, or cyclic C<sub>1</sub>-C<sub>5</sub> alkyl;

q is an integer 0, 1, 2, 3, or 4 and


p is an integer 0, 1, or 2.

24) **(Original)** A compound of claim 23 wherein B is phenyl or pyridinyl, substituted with 1-4 halogen.

25) **(Original)** A compound as in claim 23 wherein  
M a pyridine ring substituted only by Q, and Q is  
C(S)NR<sup>4</sup>R<sup>5</sup>;  
C(O)NR<sup>7</sup>-NR<sup>4</sup>R<sup>5</sup>;

or

a group of the formula



with each of R<sup>4</sup> and R<sup>5</sup>, independently:

- (a) hydrogen,
- (b) C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl,
- (c) phenyl,
- (d) C<sub>1</sub>-C<sub>3</sub> phenyl-alkyl,
- (e) up to per-halo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, or
- (f) -(CH<sub>2</sub>)<sub>q</sub>-X, where the substituent X is pyridinyl and the variable q is preferably an integer 0 or 1, and

R<sup>6</sup> is:

- (a) hydrogen,
- (b) C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl, or
- (c) cyano.

26) **(Canceled)**


27) **(Canceled)**

28) **(Canceled)**

29) **(Previously presented)** An ester derivative of a compound of formula I of claim 1.

30) **(Previously presented)** An ester derivative of a compound of formula I of claim 10.

31) **(New)** A compound of formula (I)



I

or a pharmaceutically acceptable salt, wherein

A is phenyl,;

optionally substituted with 1-4 substituents which are independently  $R^1$ ,  $OR^1$ ,  $S(O)_pR^1$ ,  $C(O)R^1$ ,  $C(O)OR^1$ ,  $C(O)NR^1R^2$ , halogen, hydroxy, oxide, amino, cyano, or nitro;

L is  $-O-$  and B is phenyl, optionally substituted with 1-4 halogen;

M is a pyridine ring, optionally substituted with 1-3 substituents which are independently  $C_1$ - $C_5$  linear or branched alkyl,  $C_1$ - $C_5$  linear or branched haloalkyl,  $C_1$ - $C_3$  alkoxy, hydroxy, oxide, amino,  $C_1$ - $C_3$  alkylamino,  $C_1$ - $C_6$  dialkylamino, halogen, or nitro;


Q is:

(1)  $C(S)NR^4R^5$ ;

(2)  $C(O)NR^7-NR^4R^5$ ;

or

(3) a group of the formula



wherein each of  $R^1$ ,  $R^2$ ,  $R^4$  and  $R^5$  is independently

(a) hydrogen,

(b)  $C_1$ - $C_5$  linear, branched, or cyclic alkyl,

(c) phenyl,

(d)  $C_1$ - $C_3$  phenyl-alkyl,

(e) up to per-halo substituted  $C_1$ - $C_5$  linear or branched alkyl, or

(f)  $-(\text{CH}_2)_q\text{-X}$ , where X is pyridine;

$\text{R}^6$  is independently

(a) hydrogen,


(b)  $\text{C}_1\text{-C}_5$  linear, branched, or cyclic alkyl, or

(c) up to per-halo substituted  $\text{C}_1\text{-C}_5$  linear or branched alkyl. or

q is an integer 0, 1, 2, 3, or 4 and

p is an integer 0, 1, or 2.

32) **(New)** A compound of formula (I)



or a pharmaceutically acceptable salt, wherein

A is pyridine optionally substituted with 1-4 substituents which are independently  $\text{R}^1$ ,  $\text{OR}^1$ ,  $\text{S(O)}_p\text{R}^1$ ,  $\text{C(O)R}^1$ ,  $\text{C(O)OR}^1$ ,  $\text{C(O)NR}^1\text{R}^2$ , halogen, hydroxy, oxide, amino, cyano, or nitro;

L is  $-\text{O}-$  and B is phenyl, optionally substituted with 1-4 halogen;

M is a pyridine ring, optionally substituted with 1-3 substituents which are independently  $\text{C}_1\text{-C}_5$  linear or branched alkyl,  $\text{C}_1\text{-C}_5$  linear or branched haloalkyl,  $\text{C}_1\text{-C}_3$  alkoxy, hydroxy, oxide, amino,  $\text{C}_1\text{-C}_3$  alkylamino,  $\text{C}_1\text{-C}_6$  dialkylamino, halogen, or nitro;


Q is:

(1)  $\text{C(S)NR}^4\text{R}^5$ ;

(2)  $\text{C(O)NR}^7\text{-NR}^4\text{R}^5$ ;

or

(3) a group of the formula



wherein each of  $R^1$ ,  $R^2$ ,  $R^4$  and  $R^5$  is independently

- (a) hydrogen,
- (b)  $C_1$ - $C_5$  linear, branched, or cyclic alkyl,
- (c) phenyl,
- (d)  $C_1$ - $C_3$  phenyl-alkyl,
- (e) up to per-halo substituted  $C_1$ - $C_5$  linear or branched alkyl, or
- (f)  $-(CH_2)_q-X$ , where X is pyridine;


$R^6$  is independently

- (a) hydrogen,
- (b)  $C_1$ - $C_5$  linear, branched, or cyclic alkyl, or
- (c) up to per-halo substituted  $C_1$ - $C_5$  linear or branched alkyl. or

q is an integer 0, 1, 2, 3, or 4 and

p is an integer 0, 1, or 2.

33) **(New)** A compound of formula (I)



or a pharmaceutically acceptable salt, wherein

A is pyrazole optionally substituted with 1-4 substituents which are independently  $R^1$ ,  $OR^1$ ,  $S(O)_pR^1$ ,  $C(O)R^1$ ,  $C(O)OR^1$ ,  $C(O)NR^1R^2$ , halogen, hydroxy, oxide, amino, cyano, or nitro;

L is  $-O-$  and B is phenyl, optionally substituted with 1-4 halogen;

M is a pyridine ring, optionally substituted with 1-3 substituents which are independently C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy, oxide, amino, C<sub>1</sub>-C<sub>3</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> dialkylamino, halogen, or nitro;


Q is:

(1) C(S)NR<sup>4</sup>R<sup>5</sup>;

(2) C(O)NR<sup>7</sup>-NR<sup>4</sup>R<sup>5</sup>;

or

(3) a group of the formula



wherein each of R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> is independently

(a) hydrogen,

(b) C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl,

(c) phenyl,

(d) C<sub>1</sub>-C<sub>3</sub> phenyl-alkyl,

(e) up to per-halo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, or

(f) -(CH<sub>2</sub>)<sub>q</sub>-X, where X is pyridine;

R<sup>6</sup> is independently

(a) hydrogen,

(b) C<sub>1</sub>-C<sub>5</sub> linear, branched, or cyclic alkyl, or

(c) up to per-halo substituted C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl. or

q is an integer 0, 1, 2, 3, or 4 and

p is an integer 0, 1, or 2.

34) **(New)** A pharmaceutical composition which comprises an effective amount of at least one compound of claim 4 and a physiologically acceptable carrier.

35) **(New)** A pharmaceutical composition which comprises an effective amount of at least one compound of claim 4 and a physiologically acceptable carrier.

36) **(New)** A pharmaceutical composition which comprises an effective amount of at least one compound of claim 19 and a physiologically acceptable carrier.

37) **(New)** A pharmaceutical composition which comprises an effective amount of at least one compound of claim 22 and a physiologically acceptable carrier.

38) **(New)** A pharmaceutical composition which comprises an effective amount of at least one compound of claim 23 and a physiologically acceptable carrier.

39) **(New)** A pharmaceutical composition which comprises an effective amount of at least one compound of claim 31 and a physiologically acceptable carrier.

40) **(New)** A pharmaceutical composition which comprises an effective amount of at least one compound of claim 32 and a physiologically acceptable carrier.

41) **(New)** A pharmaceutical composition which comprises an effective amount of at least one compound of claim 33 and a physiologically acceptable carrier.